However, satisfaction about provided information is moderate

However, satisfaction about provided information is moderate. positive groups desired more supportive information. Anxiety increased in screen- positives during the screening process, but decreased to basic levels postnatally. All groups showed a strongly positive balance between perceived utility and burden of the screening program, independent on test results or background characteristics. == Conclusion == Women highly accept the non-RhD antibody screening program. However, satisfaction about provided information is moderate. Oral and written information should be provided by obstetric care workers themselves, especially to screen-positive women. == Introduction == The scope of prenatal screening has considerably widened last two decades. The number of tests increased, and the time frame expanded to preconceptional. While consensus exists about the restriction to evidence-based tests for routine use, the benefits and burden of many tests in current use are poorly documented, as is the case for screening for red blood cell (RBC) antibodies, other than Rhesus-D (RhD). Screening for non-RhD antibodies in all pregnant women has been TMCB implemented in most developed countries. In the Netherlands, screening for those so called non-RhD antibodies, was introduced in 1998 in absence of evidence TMCB of its effectiveness and costs [1,2]. Clinically relevant non-RhD antibodies can cross the placenta and may, like RhD antibodies, induce hemolytic disease of the fetus and newborn (HDFN). HDFN is a serious condition that can give rise to fetal hydrops, fetal death or neonatal hyperbilirubinemia, resulting in permanent neurological damage by kernicterus. The obvious objective of the non-RhD screening program is timely detection of pregnancies at risk of severe HDFN, as this condition can be effectively treated by intra uterine transfusions and/or postnatal exchange transfusions in severe cases, or by postnatal phototherapy and/or blood transfusions in moderate cases [3-5]. Moreover, screening during pregnancy facilitates quick identification of the specificity of detected antibodies, if a blood transfusion to the mother is necessary during delivery. Despite the face validity of this TMCB approach, which facilitated its introduction, empirical evidence is limited compared to the evidence supporting screening for RhD antibodies. For this reason the Dutch screening program was evaluated in a nation-wide study [6]. The results of this study show that, if we compare screening for non-RhD antibodies and for RhD antibodies, the prevalence of non-RhD antibodies is about fourfold (328/100,000 versus 75/100,000). However, the number needed to screen (NNS) do detect severe HDFN, due to non-RhD antibodies is 20,000, compared to 4,000 to detect severe HDFN by RhD antibodies This is due to two reasons. First, many pregnant women show non-RhD antibodies due to previous blood transfusions (transfusions are RhD matched). For this reason in about 40% of the non-RhD positive pregnancies the father and also the fetus is antigen-negative for the blood group antigen against which the maternal antibodies are directed; in these cases the fetus is not at risk of developing HDFN [6]. In case of RhD antibodies almost all fathers are antigen-positive, which underlies the observed immunization [7]. Second, among many non-RhD antibodies, only few (only anti-K, anti-c, anti-C, anti-e and anti-E) actually can cause severe HDFN [3,6]. Combining probabilities it turns out that TMCB about 1:50 of pregnancies with non-RhD antibodies results in severe HDFN versus 1:4 of pregnancies with RhD-antibodies [6]. Because of the high NNSs of the non-RhD screening program compared to RhD screening, the acceptance of the non-RhD screening program by pregnant Mouse monoclonal to P504S. AMACR has been recently described as prostate cancerspecific gene that encodes a protein involved in the betaoxidation of branched chain fatty acids. Expression of AMARC protein is found in prostatic adenocarcinoma but not in benign prostatic tissue. It stains premalignant lesions of prostate:highgrade prostatic intraepithelial neoplasia ,PIN) and atypical adenomatous hyperplasia. women, a prerequisite following the Wilson & Jngner criteria [8], is in particular important. This paper explores the attitude towards the screening program among several groups of pregnant women, relating acceptance to being informed and experienced burden. Also it reports the experienced burden of the screening process in all its stages. This report is part of a nation-wide.